Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study

Ji Hoon Kim; Hee-Chul Nam; Chang-Wook Kim; Hee Sun Cho; Jae-Sung Yoo; Ji Won Han; Jeong Won Jang; Jong Young Choi; Seung Kew Yoon; Hyun Yang; Si Hyun Bae; Suho Kim; Jung Suk Oh; Ho Jong Chun; Chang Ho Jeon; Jaegyoon Ahn; Pil Soo Sung

doi:10.3390/cancers15174233

Cancers (Aug 2023)

Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study

Ji Hoon Kim,
Hee-Chul Nam,
Chang-Wook Kim,
Hee Sun Cho,
Jae-Sung Yoo,
Ji Won Han,
Jeong Won Jang,
Jong Young Choi,
Seung Kew Yoon,
Hyun Yang,
Si Hyun Bae,
Suho Kim,
Jung Suk Oh,
Ho Jong Chun,
Chang Ho Jeon,
Jaegyoon Ahn,
Pil Soo Sung

Affiliations

Ji Hoon Kim: Department of Gastroenterology and Hepatology, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Hee-Chul Nam: Department of Gastroenterology and Hepatology, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Chang-Wook Kim: Department of Gastroenterology and Hepatology, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Hee Sun Cho: Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Jae-Sung Yoo: Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Ji Won Han: Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Jeong Won Jang: Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Jong Young Choi: Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Seung Kew Yoon: Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Hyun Yang: Department of Gastroenterology and Hepatology, Eunpyeong St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Si Hyun Bae: Department of Gastroenterology and Hepatology, Eunpyeong St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Suho Kim: Department of Radiology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Jung Suk Oh: Department of Radiology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Ho Jong Chun: Department of Radiology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Chang Ho Jeon: Department of Radiology, Eunpyeong St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
Jaegyoon Ahn: Department of Computer Science & Engineering, Incheon National University, Incheon 22573, Republic of Korea
Pil Soo Sung: Department of Gastroenterology and Hepatology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea

DOI: https://doi.org/10.3390/cancers15174233
Journal volume & issue: Vol. 15, no. 17
p. 4233

Abstract

Read online

This study aimed to compare the prognosis and characteristics of patients with advanced hepatocellular carcinoma treated with first-line atezolizumab plus bevacizumab (AB) combination therapy and hepatic artery infusion chemotherapy (HAIC). We retrospectively assessed 193 and 114 patients treated with HAIC and AB combination therapy, respectively, between January 2018 and May 2023. The progression-free survival (PFS) of patients treated with AB combination therapy was significantly superior to that of patients treated with HAIC (p p = 0.5617 and 0.3522, respectively). In conclusion, our propensity score study reveals no significant differences in OS and PFS between patients treated with AB combination therapy and those treated with HAIC.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords